Key Takeaways ALNY secured EC approval to expand Amvuttra's use to treat ATTR-CM in adult patients. Approval was based on HELIOS-B data showing mortality, CV event and symptom improvement. Amvuttra is now the first RNAi therapy approved in the EU for both ATTR-CM and hATTR-PN.Alnylam Pharmaceuticals, Inc. (ALNY) announced that the European Commission (EC) has approved a label expansion of its RNAi therapeutic Amvuttra.The EC has now approved Amvuttra for the treatment of wild-type or hereditary transthyre ...